renal failure

EIPA (L593754) is a TRPP3 channel inhibitor (IC50=10.5 μM) and an inhibitor of Na+ H+ exchange (NHE). EIPA inhibits megacytosis, promotes autophagy, and can be used in inflammation and tumor studies.

JP1302 is a selective α2C adrenoceptor antagonist with a Kb value of 16 nM and a Ki of 28 nM for human α2C receptors.JP1302 has antidepressant activity, disrupts the FACT complex and degrades histone H1.JP1302 has been used in the study of neuropsychiatric disorders, acute renal failure, and renal injury.

Diaziquone (NSC-182986) is a water-soluble synthetic azacyclic benzoquinone that enhances penetration of the blood-brain barrier, has antitumor activity, and is used in the treatment of extreme renal failure.

D-Mannitol (Mannitol) is a diuretic and renal diagnostic aid related to sorbitol. It has little significant energy value as it is largely eliminated from the body before any metabolism can take place. It can be used to treat oliguria associated with kidney failure or other manifestations of inadequate renal function and has been used for determination of glomerular filtration rate. D-Mannitol is also commonly used as a research tool in cell biological studies, usually to control osmolarity.

Levocarnitine propionate hydrochloride (ST-261) is used for the treatment of the deterioration of renal function, congestive heart failure, intermittent claudication, and other diseases.

Torsemide (AC-4464) is an anilinopyridine sulfonylurea belonging to the class of loop diuretics. Torsemide has a prolonged duration of action compared to other loop diuretics, is extensively protein bound in plasma and has a relatively long half-life.

Irbesartan (SR-47436) is an Angiotensin 2 Receptor Blocker whose mechanism of action involves antagonizing the Angiotensin 2 Receptor.

5-Hydroxy-1-methylhydantoin (HD-003) is an antioxidant potentially for the treatment of renal failure. A creatinine metabolite, 5-Hydroxy-1-methylhydantoin , a hydroxyl radical scavenger, has previously been shown to confer renoprotection by inhibiting the progression of chronic kidney disease in rats. 5-Hydroxy-1-methylhydantoin is a novel anti-oxidant drug completely suppressed the expression of B2-kinin receptors (B2KR) in response to high glucose (25 mM) stimulation in VSMC and was also shown to attenuate the effects of BK on VSMC remodeling. 5-Hydroxy-1-methylhydantoin inhibited the BK-induced increase in MAPK phosphorylation and attenuated the increase in connective tissue growth factor (CTGF) protein levels in VSMC. These findings suggest that 5-Hydroxy-1-methylhydantoin may confer vascular protection against high glucose concentrations and BK-stimulation to ameliorate vascular injury and remodeling through its anti-oxidant properties.

D(+)-Galactosamine hydrochloride (D-Galactosamine HCl) hepatotoxicity is associated with endotoxin sensitivity and mediated by lymphoreticular cells in mice.

Glycocyamine (2-Guanidinoacetic acid), a precursor of creatine, is a replacement of dietary arginine and could support overall energy homeostasis of the bird. Glycocyamine is an important marker for renal failure, kidney transplantation, and the renal metabolic activity. The compound is a metabolite of guanidine.

Methylguanidine (MG) is a guanidine compound deriving from protein catabolism. It is also a product of putrefaction. Methylguanidine is a suspected uraemic toxin that accumulates in renal failure, however it also exhibits anti-inflammatory effects. Methyl

Temocapril is an inhibitor of tyrosine kinase.

Demeclocycline (Declostatin) is a tetracycline antibiotic produced by a strain of Streptomyces aureofaciens.Demeclocycline has antimicrobial activity and inhibits the action of vasopressin on the renal tubules, leading to diuresis. Demeclocycline can be used to induce diuresis and acute renal failure.

Paricalcitol-D6 is the deuterated form of Paricalcitol, which is used for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic renal failure.

Rolofylline (KW-3902) is a selective adenosine A1 receptor antagonist utilized in research on acute congestive heart failure, renal dysfunction, and neurodegenerative disorders.

Zardaverine (BY 290) is an orally available, selective and potent PDE3 4 inhibitor with bronchodilator activity and anti-hepatocarcinogenic activity.Zardaverine's action in platelets is mediated by PDE III isoenzymes and can be used in studies of acute renal failure and chronic airflow obstruction.

Esmolol acid (ASL-8123) hydrochloride is a mild antagonist of β-adrenergic receptors. It inhibits the heart rate and diastolic pressure responses induced by Isoproterenol in a dose-dependent manner and is applicable for renal failure research.

S3226 is an inhibitor of Na+ H+ exchanger 3 (NHE3), with an IC50 of 0.2 µmol L in rat fibroblasts transfected with NHE3. It exhibits protective effects in a rat model of ischemic acute renal failure.

Magnesium Lithospermate B is a natural product activates eNOS and ameliorates endothelial dysfunction in diabetes by enhancing vasodilation in addition to reducing oxidative stress, it can protecte cardiomyocytes from ischemic injury through specific inhibition of TAB1-p38 apoptosis signaling.improves renal failure.

Ea-230 is an immunomodulator that may be used in the treatment of renal failure.

Naxifylline is an A1 adenosine receptor antagonist that promotes urine volume to prevent the decline in renal function observed during diuretic therapy for the treatment of edema associated with congestive heart failure.

Ozolinone is an active metabolite of etozoline which acts as a loop diuretic --- a diuretic that acts at the ascending limb of the loop of Henle in the kidney. Loop diuretics are primarily used in medicine to treat hypertension and edema often due to cong

Acecainide hydrochloride (NAPA) is the major hepatic metabolite of procainamide and its antiarrhythmic effects may lead to cardiotoxicity in renal failure.

Azilsartan mepixetil is a potent angiotensin II receptor antagonist with enhanced efficacy and prolonged duration of action. It exhibits more prominent and sustained effects in lowering blood pressure and heart rate, while maintaining a high level of safety. Furthermore, Azilsartan mepixetil demonstrates optimal protective efficacy for cardiovascular and renal functions. Hence, it holds promise for the research and treatment of hypertension, chronic heart failure, and diabetic nephropathy.